已收盘 03-28 16:00:00 美东时间
+0.496
+8.00%
An announcement from Precipio Inc (PRPO) is now available. Precipio, Inc is set...
03-27 04:53
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.The
2023-10-18 21:06
Precipio (NASDAQ:PRPO) is set to give its latest quarterly earnings report on T...
2023-08-17 00:01
The following features make this product the most advanced BCR-ABL panel on the market, besting competition in terms of robust coverage, workflow ease, accuracy, and cost:1. Industry leading clinical coverage
2023-08-08 21:15
 During Thursday, 35 stocks hit new 52-week lows. Areas of Interest Abou...
2023-06-09 00:25
Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210
2023-05-22 23:03
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additional
2023-05-04 22:03
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum
2023-04-28 19:28
Shares of Precipio, Inc. (NASDAQ:PRPO – Get Rating) passed below its two hundre...
2023-03-22 15:30